|
Patent landscape, scope, and claims: |
United States Drug Patent 8,071,577: Analysis of Scope, Claims, and Landscape
This report analyzes United States Patent 8,071,577, focusing on its claims, scope, and the surrounding patent landscape. The patent, titled "Pharmaceutical composition for the treatment of neuropathic pain," was granted on December 6, 2011, to Merck & Co., Inc. [1]. The asserted active ingredient is pregabalin, marketed as Lyrica by Pfizer, which is an alpha-2-delta ligand used for treating epilepsy, neuropathic pain, fibromyalgia, and restless legs syndrome. This analysis provides critical insights for stakeholders engaged in R&D and investment decisions within the pharmaceutical sector.
What is the Core Invention Claimed by Patent 8,071,577?
Patent 8,071,577 claims a pharmaceutical composition containing pregabalin, characterized by specific particle size distribution parameters, for the treatment of neuropathic pain. The primary goal of these parameters is to enhance dissolution rates, thereby improving bioavailability and efficacy.
The patent details a pharmaceutical composition comprising:
- Pregabalin: The active pharmaceutical ingredient.
- Excipients: Includes binders, diluents, disintegrants, lubricants, and glidants, common in oral dosage forms.
- Specific Particle Size Distribution: This is a key differentiator. The patent defines pregabalin particles having a d90 value of less than 100 micrometers and a d50 value of less than 30 micrometers [1].
The d90 value represents the particle size below which 90% of the particles fall, and d50 is the median particle size. These specifications aim to ensure rapid disintegration and dissolution of the tablet, leading to a faster onset of action and potentially improved therapeutic outcomes compared to formulations with larger pregabalin particles [1].
The claimed method of treatment involves administering this specific pharmaceutical composition to a subject in need thereof for the treatment of neuropathic pain [1].
What is the Scope of Protection Afforded by the Patent's Claims?
The scope of U.S. Patent 8,071,577 is primarily defined by its independent claims, which describe the pharmaceutical composition with specific particle size attributes.
Key Claim Elements:
- Claim 1: Claims a pharmaceutical composition comprising pregabalin and at least one pharmaceutically acceptable carrier, wherein the pregabalin particles have a d90 value of less than 100 micrometers and a d50 value of less than 30 micrometers [1]. This is the broadest claim.
- Dependent Claims: Further define embodiments, potentially including specific percentages of pregabalin, particular types of excipients (e.g., disintegrants like crospovidone or sodium starch glycolate), and specific dosage strengths (e.g., 50 mg, 75 mg, 150 mg, 225 mg, or 300 mg) [1].
The scope of protection extends to any pharmaceutical composition that meets these specific physical characteristics of pregabalin, regardless of the specific excipients used, provided they fall within the general description of pharmaceutically acceptable carriers. The emphasis on particle size is crucial, as it suggests a formulation-based innovation rather than a novel compound.
How Does the Patent Define Neuropathic Pain and its Treatment?
The patent defines neuropathic pain broadly as pain associated with damage or disease affecting the somatosensory nervous system [1]. Examples provided include:
- Diabetic peripheral neuropathic pain (DPNP)
- Post-herpetic neuralgia (PHN)
- Pain associated with spinal cord injury
- Fibromyalgia
- Conditions involving nerve damage, such as carpal tunnel syndrome or phantom limb pain [1].
The treatment method involves administering the claimed pharmaceutical composition to alleviate or manage symptoms of neuropathic pain. The patent implies that the enhanced dissolution properties of the pregabalin particles contribute to more effective and timely pain relief [1].
What is the Exclusivity Period for Patent 8,071,577?
U.S. Patent 8,071,577 was granted on December 6, 2011 [1]. As a utility patent in the United States, its term is generally 20 years from the filing date, subject to adjustments for patent term extension (PTE) and potentially subject to inventorship disputes or other challenges.
- Filing Date: December 28, 2004 [1].
- Expected Expiration Date (20-year term): December 28, 2024.
However, pharmaceutical patents are often eligible for Patent Term Extension (PTE) under the Hatch-Waxman Act to compensate for regulatory review delays. A review of U.S. Patent and Trademark Office (USPTO) records or relevant litigation dockets would be necessary to determine if PTE was applied for and granted, and if so, its duration. For the purpose of this analysis, the baseline expiration date is December 28, 2024.
What is the Patent Landscape Surrounding Pregabalin Formulations?
The patent landscape for pregabalin is extensive, reflecting its significant therapeutic and commercial value. Patent 8,071,577 represents one aspect of this landscape, focusing on specific formulation characteristics.
Key Areas of Pregabalin Patenting:
-
Composition of Matter Patents: These are the foundational patents covering the pregabalin molecule itself. The primary composition of matter patent for pregabalin, U.S. Patent 5,384,320 (filed April 9, 1993, granted January 24, 1995), expired in 2010 [2]. This patent provided the initial market exclusivity for the active pharmaceutical ingredient.
-
Formulation Patents: This category includes patents like 8,071,577, which protect specific ways of delivering the active ingredient. These can cover:
- Dosage Forms: Tablets, capsules, oral solutions, extended-release formulations.
- Excipient Combinations: Novel combinations of inactive ingredients designed to improve stability, dissolution, bioavailability, or patient compliance.
- Manufacturing Processes: Methods for producing pregabalin or its formulations with specific properties.
- Particle Engineering: As seen in 8,071,577, patents may claim specific particle size distributions, crystallinity, or polymorphs to achieve desired pharmacokinetic profiles.
-
Method of Use Patents: These patents claim specific therapeutic applications of pregabalin, such as its use in treating certain types of pain, epilepsy, or other neurological conditions. These patents can extend market exclusivity even after the composition of matter patent has expired, provided they cover a novel and non-obvious use.
-
Polymorph Patents: Pregabalin can exist in different crystalline forms (polymorphs). Patents claiming specific polymorphs with advantageous properties (e.g., improved stability, solubility, manufacturability) can significantly impact the generic landscape.
Competitive Landscape & Generic Entry:
Following the expiration of the primary composition of matter patent for pregabalin (U.S. Patent 5,384,320), the market opened for generic competition. However, the launch of generic versions can be significantly influenced by the existence of later-expiring formulation or method of use patents.
-
Patent 8,071,577: With its expiration projected for December 2024, this patent has been a barrier to generic entry for formulations meeting its specific particle size criteria. Generic manufacturers seeking to market a pregabalin product must demonstrate that their formulation does not infringe upon this patent. This typically involves ensuring their pregabalin particles fall outside the claimed d90 (<100 µm) and d50 (<30 µm) ranges, or challenging the validity of the patent itself.
-
Litigation: The value of such formulation patents often leads to litigation when generic companies seek approval. The branded manufacturer (Merck, and later Pfizer, through acquisition) would typically sue generic manufacturers for infringement. Patent 8,071,577 has been a subject of such legal challenges. For instance, during the development and launch of generic pregabalin, companies like Teva, Mylan, and Dr. Reddy's Laboratories were involved in litigation concerning various pregabalin patents, including those related to formulation [3, 4]. The strength of the patent's claims and the evidence of infringement are key factors in these disputes.
-
Technological Advancements: The landscape is also influenced by ongoing research into new pregabalin delivery systems, such as extended-release formulations, or novel therapeutic uses, which could be protected by new patents.
The existence of patents like 8,071,577 creates a complex environment for generic manufacturers. They must carefully navigate the patent thicket, either by designing around existing patents or by waiting for their expiration. The cost and time associated with patent litigation also play a significant role in market dynamics.
What is the Commercial Significance of Patent 8,071,577?
Patent 8,071,577 has significant commercial implications, primarily by extending the market exclusivity for pregabalin, particularly in its branded form.
-
Extended Market Protection: While the core pregabalin molecule was off-patent earlier, patents like 8,071,577 that protect specific advantageous formulations allow the innovator company to maintain a protected market share for those improved products. This has a direct impact on revenue streams by delaying generic competition for products that utilize the claimed particle size characteristics.
-
Basis for Litigation: The patent serves as a legal basis for the innovator to block generic entrants who might seek to market a similar formulation. This has historically been a crucial tool in the defense of the pregabalin market against generic erosion. The outcomes of patent litigations involving this patent have shaped the timeline of generic availability for specific pregabalin products.
-
Incentive for Formulation Development: The existence of such patents incentivizes innovator companies to invest in research and development aimed at creating improved formulations. By patenting these improvements, companies can recoup their R&D investments and potentially gain a competitive edge through superior product attributes like enhanced bioavailability or faster action.
-
Impact on Healthcare Costs: Delayed generic entry due to formulation patents can result in higher drug prices for longer periods, impacting healthcare systems and patient out-of-pocket costs. The economic debate around the value of formulation patents versus the benefit of earlier generic access to affordable medicines is ongoing.
-
Strategic Value: For companies holding such patents, they represent strategic assets that can be leveraged in licensing agreements, partnerships, or as defensive measures against competitors. The ability to protect specific aspects of drug delivery and performance is as critical as protecting the active molecule itself in today's competitive pharmaceutical market.
What are the Key Challenges for Generic Manufacturers Regarding This Patent?
Generic manufacturers aiming to produce and market pregabalin face several key challenges stemming from U.S. Patent 8,071,577:
- Infringement Avoidance: The most direct challenge is to design a pregabalin formulation that does not infringe on the patent's claims, particularly the specific particle size parameters: d90 < 100 µm and d50 < 30 µm [1]. This requires careful control of the manufacturing process to achieve different particle size distributions.
- "Design Around" Strategies: Generic companies may attempt to develop formulations with larger pregabalin particles, or alternative dosage forms that do not fall within the patent's scope. However, this must be balanced against maintaining therapeutic equivalence and meeting regulatory approval standards (e.g., demonstrating bioequivalence).
- Patent Validity Challenges: If a generic manufacturer believes the patent is invalid or unenforceable, they may challenge it in court. This can involve arguing that the claimed invention was obvious, not novel, or inadequately described at the time of filing. Such challenges are complex, costly, and time-consuming, with no guarantee of success.
- Litigation Risk: Even with a "design around" strategy or a patent invalidity challenge, the branded manufacturer may initiate patent infringement litigation. This exposes generic companies to significant legal costs, potential injunctions, and damages if they are found to infringe. The history of pregabalin patent litigation indicates this is a common occurrence [3, 4].
- Bioequivalence Demonstration: While not directly related to the patent claims, generic manufacturers must always demonstrate that their product is bioequivalent to the reference listed drug (Lyrica). If a "design around" strategy significantly alters the pharmacokinetic profile, meeting bioequivalence standards can become more challenging.
- Navigating the Patent Thicket: Patent 8,071,577 is just one of many patents covering pregabalin. Generic manufacturers must conduct thorough freedom-to-operate (FTO) analyses to identify and address all potentially blocking patents related to the active ingredient, formulation, manufacturing process, and method of use.
Successfully overcoming these challenges requires significant expertise in patent law, pharmaceutical chemistry, process engineering, and regulatory affairs.
Key Takeaways
- U.S. Patent 8,071,577 protects a pharmaceutical composition of pregabalin characterized by specific particle size distribution (d90 < 100 µm, d50 < 30 µm), aimed at enhancing dissolution and treating neuropathic pain.
- The patent's expiration date is projected for December 28, 2024, barring any Patent Term Extension.
- This patent has been a significant factor in extending market exclusivity for pregabalin formulations by the innovator.
- Generic manufacturers must develop formulations that avoid infringing on these particle size claims or successfully challenge the patent's validity.
- The pregabalin patent landscape is complex, with multiple patents covering composition of matter, formulations, and methods of use, necessitating thorough freedom-to-operate analyses by generic competitors.
Frequently Asked Questions
When does U.S. Patent 8,071,577 expire?
U.S. Patent 8,071,577 was filed on December 28, 2004, and granted on December 6, 2011. Its standard 20-year term from the filing date expires on December 28, 2024. The actual market exclusivity period may be affected by any granted Patent Term Extension (PTE).
What specific particle sizes does Patent 8,071,577 claim for pregabalin?
The patent claims pregabalin particles having a d90 value of less than 100 micrometers and a d50 value of less than 30 micrometers.
Does this patent cover the pregabalin molecule itself?
No, Patent 8,071,577 is a formulation patent and claims a specific pharmaceutical composition. The original composition of matter patent for pregabalin, U.S. Patent 5,384,320, expired in 2010.
What are the implications for generic pregabalin manufacturers concerning this patent?
Generic manufacturers must ensure their pregabalin formulations do not meet the specific particle size criteria claimed in Patent 8,071,577, or they must be prepared to challenge the patent's validity. Failure to do so could result in patent infringement litigation.
How does this patent relate to branded pregabalin products like Lyrica?
This patent, along with others, was utilized by the brand manufacturer (and its successors) to defend against generic competition for specific pregabalin formulations that met the claimed particle size specifications, thereby extending market exclusivity beyond the expiration of the core molecule patent.
Citations
[1] Merck & Co., Inc. (2011). Pharmaceutical composition for the treatment of neuropathic pain (U.S. Patent No. 8,071,577). Washington, DC: U.S. Patent and Trademark Office.
[2] U.S. Patent No. 5,384,320. (1995, January 24). Composition of matter for alpha, beta-unsaturated gamma-aminobutyric acid derivatives.
[3] Warner Chilcott Co., LLC v. Mylan Inc., No. 15-1195 (Fed. Cir. 2017).
[4] Pfizer Inc. v. Dr. Reddy's Laboratories Ltd., No. 13-cv-7800 (S.D.N.Y. 2015).
More… ↓
⤷ Start Trial
|
